OOIR: Observatory of International Research

Papers

(The H4-Index of npj Vaccines is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Assessing immunogenicity barriers of the HIV-1 envelope trimer	210
Analyzing atomic force microscopy images of virus-like particles by expectation-maximization	133
Immunogenicity phase II study evaluating booster capacity of nonadjuvanted AKS-452 SARS-Cov-2 RBD Fc vaccine	121
Effective vaccination strategy using SARS-CoV-2 spike cocktail against Omicron and other variants of concern	116
Risk assessment of retinal vascular occlusion after COVID-19 vaccination	108
Influenza A virus in dairy cattle: infection biology and potential mammary gland-targeted vaccines	94
Microneedle patch as a new platform to effectively deliver inactivated polio vaccine and inactivated rotavirus vaccine	94
Reverse development of vaccines against antimicrobial-resistant pathogens	84
A potent and durable malaria transmission-blocking vaccine designed from a single-component 60-copy Pfs230D1 nanoparticle	78
Immunogenicity and safety of a rabies-based highly pathogenic influenza A virus H5 vaccine in cattle	77
Impact of genotypic variability of measles virus T-cell epitopes on vaccine-induced T-cell immunity	75
Zika purified inactivated virus (ZPIV) vaccine reduced vertical transmission in pregnant immunocompetent mice	68
Functionality and translation fidelity characterization of mRNA vaccines using platform based mass spectrometry detection	67
Intranasal vaccine for Lyme disease provides protection against tick transmitted Borrelia burgdorferi beyond one year	65
Rational development of a combined mRNA vaccine against COVID-19 and influenza	62
Vaccination against Onchocerca volvulus induces IgG-mediated protective immunity dependent on neutrophils and complement	62
Mapping global public perspectives on mRNA vaccines and therapeutics	62
Immunogenic arenavirus vector SIV vaccine reduces setpoint viral load in SIV-challenged rhesus monkeys	62
Protein engineering strategies for rational immunogen design	61
The dengue-specific immune response and antibody identification with machine learning	61
Baseline mapping of Oropouche virology, epidemiology, therapeutics, and vaccine research and development	59
Diversity of immunization strongly impacts SARS-CoV-2 antibody function surrogates	59
Multicomponent intranasal adjuvant for mucosal and durable systemic SARS-CoV-2 immunity in young and aged mice	59
Single-dose intranasal adenovirus-based RSV vaccines targeting G and M2	57
A rationally designed antigen elicits protective antibodies against multiple nosocomial Gram-positive pathogens	53

Genome-wide association study of myocarditis and pericarditis following COVID-19 vaccination	53
Author Correction: A Pvs25 mRNA vaccine induces complete and durable transmission-blocking immunity to Plasmodium vivax	52
IL-12 mRNA-LNP promotes dermal resident memory CD4+ T cell development	51
Next-gen novel nanocage-based multivalent vaccine candidate to tackle the rising menace of Mpox	51
Tick-borne encephalitis vaccine breakthrough infections induce aberrant T cell and antibody responses to non-structural proteins	50
Use of equine H3N8 hemagglutinin as a broadly protective influenza vaccine immunogen	50
Restricted valency (NPNA)n repeats and junctional epitope-based circumsporozoite protein vaccines against Plasmodium falciparum	48
Titers of antibodies against ancestral SARS-CoV-2 correlate with levels of neutralizing antibodies to multiple variants	48
Human in vitro modeling of adjuvant formulations demonstrates enhancement of immune responses to SARS-CoV-2 antigen	47
SARS-CoV-2 vaccination may mitigate dysregulation of IL-1/IL-18 and gastrointestinal symptoms of the post-COVID-19 condition	46
Immune response against SARS-CoV-2 variants: the role of neutralization assays	46
Multivalent cytomegalovirus glycoprotein B nucleoside modified mRNA vaccines did not demonstrate a greater antibody breadth	46
PfRH5 vaccine; from the bench to the vial	45
Vaccination with Mincle agonist UM-1098 and mycobacterial antigens induces protective Th1 and Th17 responses	45
Immune response induced by standard and fractional doses of 17DD yellow fever vaccine	44
GP38 as a vaccine target for Crimean-Congo hemorrhagic fever virus	44
A register and questionnaire study of long-term general health symptoms following SARS-CoV-2 vaccination in Denmark	44
Antibody responses against influenza A decline with successive years of annual influenza vaccination	43